Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

EU supports COVID vaccine patent waiver talks, but critics say won't solve scarcity

CoronavirusMay 06, 2021 04:16PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: European Commission President Ursula von der Leyen removes her mask while meeting with Jordan's King Abdullah II ibn Al Hussein (not pictured) in Brussels, Belgium May 5, 2021. REUTERS/Yves Herman/Pool

By Philip Blenkinsop and Carl O'Donnell

BRUSSELS/NEW YORK (Reuters) -The European Union on Thursday backed a U.S. proposal to discuss waiving patent protections for COVID-19 vaccines, but drugmakers and some other governments opposed the idea, saying it would not solve global inoculation shortages.

European Commission President Ursula von der Leyen expressed willingness to explore a waiver after President Joe Biden on Wednesday promoted the plan, reversing the U.S. position.

"The main thing is, we have to speed this up," U.S. Secretary of State Anthony Blinken said on Thursday as India battled a devastating COVID-19 outbreak. "None of us are going to be fully safe until ... we get as many people vaccinated as possible."

A patent waiver is "one possible means of increasing manufacture, and access to vaccines," he said, as the White House denied a split among officials over the waiver idea.

Biden's administration endorsed negotiations at the World Trade Organization to gain global agreement.

WTO Director-General Ngozi Okonjo-Iweala told member states that she "warmly welcomed" the U.S. move. "We need to respond urgently to COVID-19 because the world is watching and people are dying," she said.

World Health Organization (WHO) chief Tedros Adhanom Ghebreyesus reached for capital letters in a tweet calling Biden's move a "MONUMENTAL MOMENT IN THE FIGHT AGAINST #COVID19," and said it reflected "the wisdom and moral leadership of the United States."

Despite that enthusiasm, drugmakers, who stand to lose revenue if they are stripped of patent rights to COVID-19 vaccines, and other critics found flaws in the proposal.

The complexities of manufacturing means free access to the intellectual property is not enough to immediately increase vaccine production, they said. Moderna (NASDAQ:MRNA) waived its patent rights in October, and on Thursday noted the lack of companies able to rapidly manufacture a similar vaccine and secure approval for it.

Combined, Pfizer Inc (NYSE:PFE) and Moderna Inc have forecast over $45 billion in sales this year for their COVID-19 vaccines.

In the long term, a waiver would discourage pharmaceutical companies from rapidly responding to future global health threats with large research investments, some said.

Germany, the EU's biggest economic power and home to a large pharmaceutical sector, rejected the idea, saying vaccine shortages were due to limited production capacity and quality standards rather than patent protection issues.

Health Minister Jens Spahn said he shared Biden's goal of providing the whole world with vaccines. But a government spokeswoman said in a statement that "the protection of intellectual property is a source of innovation and must remain so in the future."

Moreover, a waiver would take months to negotiate and require unanimous agreement among the 164 countries in the WTO. Drug companies urged rich countries instead to share vaccines more generously with the developing world.

DOES NOT ADDRESS 'THE REAL CHALLENGES'

Stock prices for drugmakers largely recovered after initially falling sharply after Biden backed the waiver idea. Moderna was off 1.3% after earlier dropping 12%, and the U.S. shares of its German partner BioNTech SE (NASDAQ:BNTX) shed 0.6% after falling as much as 15% earlier. "The bottleneck is neither access nor patents (or price) butsimply that there aren't enough vials, raw materials, etc tomanufacture it regardless of patents," Jefferies (NYSE:JEF) analyst Michael Yee said of expanding COVID-19 vaccine production.

The pharmaceutical industry's main lobbying group, PhRMA, said: "This decision does nothing to address the real challenges to getting more shots in arms, including last-mile distribution and limited availability of raw materials."

There have been more than 155 million confirmed coronavirus infections worldwide and almost 3.4 million peopled have died for COVID-19, according to a Reuters tally.

But the vast bulk of the 624 million people who have received at least one dose of the vaccine, according to the Our World in Data website, live in wealthier countries.

The global COVAX vaccine distribution program, led by the WHO and the Global Alliance for Vaccines and Immunization (GAVI), that aims to supply vaccines to low-income countries, has so far handed out around 41 million doses.

French President Emmanuel Macron said he was "very much in favour" of opening up intellectual property. However, a French government official said vaccine shortages was the result of a lack of production capacity and ingredients, not of patents.

"I would remind you that it is the United States that has not exported a single dose to other countries, and is now talking about lifting the patents," the official said.

The United States has shipped a few million vaccine doses it was not using to Mexico and Canada on loan.

South Africa and India made the initial waiver proposal at the WTO in October, gathering support from many developing countries, which say it will make vaccines more widely available.

Until now, the European Union has been aligned with a group of countries, including Britain and Switzerland - home to large pharmaceutical companies - that have opposed the waiver.

EU supports COVID vaccine patent waiver talks, but critics say won't solve scarcity
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (7)
Vv Pp
Vv Pp May 06, 2021 4:25PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
lol we are still discussing about basic human rights in 21st century... public health should be a means of profit for few golden boys or not??? very difficult question indeed 🤣🤣
Simon Liu
Simon Liu May 06, 2021 1:09PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
US is removing the IP belong to Europe. While, Europe is not able to get enough production materials controlled by US. So, anyway, US wins.
Meru Pet
Meru Pet May 06, 2021 6:12AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
i believe in the "invisible hand". you can't just ask people to make efforts, to be "evil big pharma" anyway and without compensation. (i am not a shareholder of a company that produces anti covid vaccines)
Ogo Pogo
Ogo Pogo May 06, 2021 4:43AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Intellectual Property is Property and in any civilized country property is sacred. Expropriating IP is a crime. Licensing and distribution agreements should be negotiated.
Val Lange
Val Lange May 06, 2021 4:38AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Remove all HIV patents and patents related to rare health problems, and future of pharmasy will be will be Chinese;)
you what
you what May 06, 2021 4:36AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
good luck forcing pharmas to update existing covid vaccines that become useless when it mutates again :)
Ogo Pogo
Ogo Pogo May 06, 2021 4:11AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Communists at the gates!!
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email